TY - JOUR
T1 - Cytogenetic and teratogenic evaluation of letimide
AU - Díaz Barriga-Arceo, S.
AU - Madrigal-Bujaidar, E.
AU - Salazar, M.
AU - Chamorro, G.
PY - 1991/4
Y1 - 1991/4
N2 - Letimide is a new efficient analgesic salicylate derivative. In this study we evaluated its cytogenetic and teratogenic potential. For chromosomal aberrations and sister chromatid exchange analysis we tested 250, 375, 500 and 625 μg ml of letimide in human lymphocyte cultures in vitro, and for the in vivo cytogenetic study analysing the same parameters we studied the effects of 30, 50 and 100 mg kg in mouse bone marrow cells. The teratogenic study was performed at dosages of 50, 100 and 200 mg/kg d of letimide in mice. The results agree with the systems studied previously, showing no significant effect in the rate of aberrations, sister chromatid exchanges or congenital malformations induced by this new analgesic.
AB - Letimide is a new efficient analgesic salicylate derivative. In this study we evaluated its cytogenetic and teratogenic potential. For chromosomal aberrations and sister chromatid exchange analysis we tested 250, 375, 500 and 625 μg ml of letimide in human lymphocyte cultures in vitro, and for the in vivo cytogenetic study analysing the same parameters we studied the effects of 30, 50 and 100 mg kg in mouse bone marrow cells. The teratogenic study was performed at dosages of 50, 100 and 200 mg/kg d of letimide in mice. The results agree with the systems studied previously, showing no significant effect in the rate of aberrations, sister chromatid exchanges or congenital malformations induced by this new analgesic.
KW - Analgesic
KW - Cytogenetics in vivo and in vitro
KW - Letimide
KW - Salicylate derivative
KW - Teratogenesis
UR - http://www.scopus.com/inward/record.url?scp=0026033315&partnerID=8YFLogxK
U2 - 10.1016/0378-4274(91)90095-N
DO - 10.1016/0378-4274(91)90095-N
M3 - Artículo
SN - 0378-4274
VL - 56
SP - 99
EP - 107
JO - Toxicology Letters
JF - Toxicology Letters
IS - 1-2
ER -